Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Pfizer Long-Acting CCBs Safe for Hypertension Treatment ORLANDO, Fla., March 26, 1996 -- A leading medical researcher presented data today on 35,000 patients supporting the safety of Norvasc (amlodipine bcsylate) and Procardia XL (nifedipine GITS) for treating hypertension. Speaking at the American College of Cardiology meeting here, Dr. Robert A. Kloner, M.D., Ph.D., of Good Samaritan Hospital in Los Angeles, said hypertensive patients treated with Norvasc or Procardia XL had low rates of heart attack which were similar to those seen with other anti-hypertensive medications. This analysis is based on patients in worldwide prospectively designed clinical trials which were sponsored by Pfizer. Dr. Kloner distinguished between the modern, once-a-day calcium channel blockers Procardia XL and Norvasc and older, three to four times a day calcium channel blockers which are generally approved for angina, not hypertension. Procardia XL and Norvasc "do not cause big swings in blood levels and in general are not associated with increased heart rates, precipitous falls in blood pressure, or increased sympathetic nervous system activity," Dr. Kloner said. "The extensive review conducted by Dr. Kloner, is further evidence of the safety of these medications and reflects the daily clinical experience of thousands of physicians and their patients around the world," said Dr. Roger Sachs, senior vice president, Medical Affairs for Pfizer. "Physicians know that long-acting calcium channel blockers are highly effective in lowering blood pressure and the data presented today underscore their safety." In addition, several researchers at ACC discussed the importance of results from the PRAISE trial, in which Norvasc was demonstrated to be safe for use in patients with congestive heart failure. Prescribing information for Norvasc and Procardia XL is available from Pfizer. Pfizer Inc. (NYSE: PFE) is a diversified, research-based health care company with global operations. In 1995, the company reported sales of approximately $10 billion and the company plans to invest approximately $1.7 billion in research and development in 1996. E-mail this page to a friend or colleague! To print, use this version